ABL Bio Inc.
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Oct 2033
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Aug 6, 2027The maintenance fee for Anti-B7-H3 antibody and use thereof (US 11,891,445) comes due Aug 6, 2027. Unpaid by Feb 7, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,598,483 | Monoclonal antibody binding specifically to DLL4 and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,184,010 | Dual-targeting protein binding specifically to DLL4 and VEGF and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 12,624,110 | Antibody to Insulin-Like Growth Factor 1 Receptor (IGF1R) and Related Compositions and Uses In force · Medium confidence | In force | Medium confidence | |
| US 12,071,483 | Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,891,445 | Anti-B7-H3 antibody and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 12,168,690 | Anti-EGFR/anti-4-1BB bispecific antibody In force · From the USPTO record | In force | From the USPTO record | |
| US 12,240,913 | Anti-HER2/anti-4-1BB bispecific antibody and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 12,122,830 | ANTI-ROR1 Antibody and Use Thereof In force · High confidence | In force | High confidence | |
| US 12,173,070 | Anti-PD-L1/anti-LAG3 bispecific antibodies and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 12,049,493 | Anti-alpha-synuclein antibodies and uses thereof In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 14: 3 patents in force now held by others · 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
13 pending · 3 abandoned · 1 no status recorded